@article{33b5231bd5a94b9d8a52b626d9c4ca5d,
title = "Cumulative burden of depression and all-cause mortality in women living with human immunodeficiency virus",
abstract = "Background Research linking depression to mortality among people living with human immunodeficiency virus (PLWH) has largely focused on binary {"}always vs never{"} characterizations of depression. However, depression is chronic and is likely to have cumulative effects on mortality over time. Quantifying depression as a cumulative exposure may provide a better indication of the clinical benefit of enhanced depression treatment protocols delivered in HIV care settings. Methods Women living with HIV (WLWH), naive to antiretroviral therapy, from the Women's Interagency HIV Study were followed from their first visit in or after 1998 for up to 10 semiannual visits (5 years). Depressive symptoms were assessed using the Center for Epidemiologic Studies Depression (CES-D) scale. An area-under-the-curve approach was used to translate CES-D scores into a time-updated measure of cumulative days with depression (CDWD). We estimated the effect of CDWD on all-cause mortality using marginal structural Cox proportional hazards models. Results Overall, 818 women contributed 3292 woman-years over a median of 4.8 years of follow-up, during which the median (interquartile range) CDWD was 366 (97-853). Ninety-four women died during follow-up (2.9 deaths/100 woman-years). A dose-response relationship was observed between CDWD and mortality. Each additional 365 days spent with depression increased mortality risk by 72% (hazard ratio, 1.72; 95% confidence interval, 1.34-2.20). Conclusions In this sample of WLWH, increased CDWD elevated mortality rates in a dose-response fashion. More frequent monitoring and enhanced depression treatment protocols designed to reduce CDWD may interrupt the accumulation of mortality risk among WLWH.",
keywords = "HIV/AIDS, cumulative burden of depression, mental illness, mortality",
author = "Mills, {Jon C.} and Pence, {Brian W.} and Todd, {Jonathan V.} and Bengtson, {Angela M.} and Breger, {Tiffany L.} and Andrew Edmonds and Cook, {Robert L.} and Adebola Adedimeji and Schwartz, {Rebecca M.} and Seble Kassaye and Joel Milam and Jennifer Cocohoba and Mardge Cohen and Elizabeth Golub and Gretchen Neigh and Margaret Fischl and Kempf, {Mirjam Colette} and Adimora, {Adaora A.}",
note = "Funding Information: Potential conflicts of interest. M. F. reports grants from NIH during the conduct of the study. A. A. A. reports grants from NIH during the conduct of the study and grants from Gilead and personal fees from Merck outside the submitted work. A. E. reports grants from NIH during the conduct of the study. M. C. reports grants from NIH during the conduct of the study. All remaining authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Funding Information: Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH; T32 AI007001 to A. A.) and the Women{\textquoteright}s Interagency HIV Study, a NIH-funded program made possible by the NIAID, Eunice Kennedy Shriver National Institute of Child Health and Human Services, National Cancer Institute, National Institute on Drug Abuse, and the National Institute on Mental Health (grants n U01-AI-103401 to M. K.; U01-AI-103408, U01-AI-035004, U01-AI-031834, and U01-AI-034993 to M. C.; U01-AI-034994 to S. K.; U01-AI-103397 to M. F.; U01-AI-103390 to A. A.; U01-AI-034989 and U01-AI-042590 to E. G.; and U01-HD-032632 to J. M.). Targeted supplemental funding for specific projects is also provided by the NIH at the National Institute of Dental and Craniofacial Research, the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Deafness and other Communication Disorders, and the Office of Research on Women{\textquoteright}s Health. Women{\textquoteright}s Interagency HIV Study data collection is also supported by the University of California–San Francisco Clinical & Translational Science Institute (CTSA) (UL1-TR000004) the Atlanta CTSA (UL1-TR000454), and the University of North Carolina at Chapel Hill Center for AIDS Research (P30-AI-050410). Publisher Copyright: {\textcopyright} The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.",
year = "2018",
month = oct,
day = "30",
doi = "10.1093/cid/ciy264",
language = "English (US)",
volume = "67",
pages = "1575--1581",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "10",
}